explore -WSS

explore

author：knowledge 2025-09-03 14:35:39 - browse：45

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： House panel takes first step toward fixing drug shortages

hotspot

WSS

State of the Union pitch: Bigger Medicare drug price negotiations

PBMs drew scrutiny in House hearing — and so did pharma

Microsoft's Peter Lee: Generative AI could help doctors be more human

How the messy conversation about Dolly changed bioethics

Senate bill would ban some hospital facility fees

Medicare to pay more for cardiac rehab in hospital outpatient clinics

hotspot

explore

Gilead needs Arcellx more than ever

leisure time

Cancer drug shortages should be causing more outrage

Why the drug industry's warnings on the IRA's impact fall short

Novavax promises a turnaround & Lilly roils the obesity market

IVF doctors demand details after CooperSurgical lawsuit

Guidelines to prevent youth baseball injuries need more muscle

PBMs drew scrutiny in House hearing — and so did pharma

BioMarin wins approval for gene therapy to treat hemophilia A

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Anesthesiologist group: stop taking Ozempic before surgery

People with substance use disorder deserve online privacy

hotspot

Why Talkspace is targeting Medicare, a tricky market

Medicare to pay more for cardiac rehab in hospital outpatient clinics

He's 19 months old and has one of the world’s rarest diseases

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Families look for replacement for GSK asthma drug Flovent

The struggle to figure out which patients 'deserve' Wegovy

hotspot

hotspot

hotspot

focus